Federal investment in RNA vaccine research has supported nearly three decades of scientific work spanning infectious diseases, cancer, and vaccine development, but recent and proposed funding cuts ...

Emerging modalities such as self-amplifying and circular RNA, expanding oncology and rare-disease applications, and scalable manufacturing are creating high-growth investment avenues, supported by ...

Driving RNA vaccine innovation through microbiome insights is an emerging frontier that moves beyond pathogen-only thinking and toward vaccines designed ...

Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If ...

Moderna has managed to eke out some temporary wins, paving the way for the homegrown biotech to focus on its next moves.

Commissioner Marty Makary defended his agency's position and record on mRNA vaccines, days after it changed course and agreed ...

As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.

Singling out Health Secretary Robert F. Kennedy Jr.’s worst decision is difficult, because the competition is fierce, but near the top of the list was his decision to terminate a series of federal ...

The recommendation from regulators paves the way for the shot’s approval in the European Union at a time the company is ...

The European Medicines Agency (EMA) announced Friday it has recommended Moderna’s combined mRNA COVID-19 and flu vaccine be ...

The cold season is in full swing, throats are scratchy and noses are running. We feel ill and hope it is not the flu. The ...